PASITHEA THERAPEUTICS news, videos and press releases
For more news please use our advanced search feature.
PASITHEA THERAPEUTICS - More news...
PASITHEA THERAPEUTICS - More news...
- Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
- Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
- Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
- Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
- Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
- Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
- Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
- Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
- Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
- Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
- Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
- Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
- Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
- Pasithea Therapeutics Announces Results from 2023 Annual Meeting
- Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
- Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
- Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
- Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
- Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
- Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
- Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
- Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
- Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
- Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors
- Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
- Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.
- Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference
- Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
